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Global18 years, with type 1 diabetes (n = 8022) or type 2 diabetes (n = 19,563) treated with insulin
for >12 months, at 2004 sites in 24 countries worldwide.
Results: Increased blood glucose monitoring (69.7%) and seeking medical assistance (62.0%)
were the most common responses in the 4 weeks following hypoglycaemic events for
patients with type 1 diabetes and type 2 diabetes, respectively. Approximately 44% of
patients with type 1 diabetes or type 2 diabetes increased calorie intake in response to a
hypoglycaemic episode. Following hypoglycaemia, 3.9% (type 1 diabetes) and 6.2% (type 2
diabetes) of patients took leave from work or study. Regional differences in fear of, and
responses to, hypoglycaemia were evident – in particular, a lower level of hypoglycaemic
fear and utilisation of healthcare resources in Northern Europe and Canada.
Conclusions: Hypoglycaemia has a major impact on patients and their behaviour. These glo-
bal data for the first time reveal regional variations in response to hypoglycaemia and high-
light the importance of patient education and management strategies.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tight glycaemic control achieved through intensive insulin
regimens has been shown to reduce the risk of long-term
complications of diabetes and is often the goal of treatment
for both type 1 and type 2 diabetes [1–4]. However, insulin
therapy, and particularly intensive insulin therapy, is associ-
ated with an increased risk of hypoglycaemia [1–3]. Hypogly-
caemia, in addition to morbidity and mortality, is associated
with a reduction in health-related quality of life, increased
fear and anxiety, reduced productivity and increased health-
care costs through increased utilisation of healthcare
resources and blood glucose monitoring [5–8]. As a result,
patients may take compensatory actions in order to avoid
hypoglycaemia, such as reducing their insulin dose, reducing
exercise levels or increasing their calorie intake [9,10], which
can lead to poor glycaemic control.
Currently, the majority of data on the prevalence of hypo-
glycaemia and its consequences come from industrialised
Western countries [1,7,9–13], with multinational studies
focusing on economies with advanced healthcare systems.
Estimates of the frequency of hypoglycaemia are 3.5–7.2
events/month (42–91 events per patient-year [PPY]) for type
1 diabetes [6,8,10,14] and 0.8–4.0 events/month (20.3–44.4
events PPY) for type 2 diabetes [6,8,10,14–17], and rates of
hypoglycaemia increase with duration of disease and dura-
tion of insulin treatment [18]. Increasing frequency of non-
severe hypoglycaemic events has been reported to lead to
an increased risk of severe hypoglycaemic events [19,20]. Sev-
ere hypoglycaemia, defined by the American Diabetes Associ-
ation (ADA) as requiring third-party assistance [21], accounts
for significant medical expenditure due to hospitalisation [22–
24] and a lower health-related quality of life [9], as well as
increased mortality risks [11,12]. It is not surprising that
patients respond to hypoglycaemia by taking compensatory
actions to avoid future occurrences [7].
Until now, the impact of hypoglycaemia on patient beha-
viour has not been ascertained on a truly global level due to
a requirement for systematic data capture, involving a large
number of patients from different countries. Comparing
potential country-specific differences based on current dataremains difficult due to differences between individual study
designs.
In this study, we report on patient fear of, and responses
to, hypoglycaemia from the Hypoglycaemia Assessment Tool
(HAT) study – a global, 4-week prospective study of hypogly-
caemia in clinical practice.
2. Research design and methods
2.1. Study design
This study was a non-interventional, multicentre, 4-week
prospective-cohort survey of hypoglycaemic events con-
ducted across 2004 sites in 24 countries (Argentina, Austria,
Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland,
Germany, Hungary, India, Israel, Lebanon, Malaysia, Mexico,
The Netherlands, Poland, Romania, Russia, Saudi Arabia, Ser-
bia, Slovakia, Slovenia, and Sweden). The study was con-
ducted from 2012 to 2013 in a staggered fashion (start times
varied by country). The study protocol and assessments were
conducted in accordance with the Declaration of Helsinki
(2004) and the International Conference on Harmonization
Guidelines for Good Clinical Practice (1996), and approved by
country-specific regulatory agencies.
2.2. Study population
Consecutive eligible patients were enrolled during a routine
scheduled clinical consultation with their healthcare provi-
der. Eligible patients were 18 years of age at the time of
enrolment, with type 1 diabetes or type 2 diabetes treated
with insulin for >12 months. Exclusion criteria included
non-ambulatory patients, illiterate patients or patients other-
wise unable to complete a written survey.
2.3. Study objectives
The primary endpoint was the proportion of patients experi-
encing at least one hypoglycaemic event during the 4-week
observational period (detailed methodology and results in
Khunti et al. [25]). This manuscript reports on patient knowl-
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caemia, patient actions as a result of a hypoglycaemic epi-
sode, and the impact of hypoglycaemia on work/study for
patients currently enrolled in education or in part- or full-
time employment.
2.4. Assessments
This combined cross-sectional cohort study comprised a two-
part self-assessment questionnaire (SAQ). Part 1 was used to
record baseline demographic and treatment information,
evaluate knowledge and perceptions of hypoglycaemia as
well as the history of severe hypoglycaemia over the past
6 months and symptomatic hypoglycaemia over the past
4 weeks. Fear of hypoglycaemia was reported on a 10-point
scale, with 0 as ‘not afraid at all’ and 10 as ‘absolutely terri-
fied’. Part 2 evaluated the history of both severe and symp-
tomatic hypoglycaemia over the 4 weeks following baseline
study entry, and the effect of hypoglycaemia on patient beha-
viour and productivity during this time frame. To assist recall
in Part 2 of the SAQ, patients were provided with a diary to
summarise their experience of hypoglycaemia at home and
to help track them over the 4-week period. All study materials
were translated into local languages, and data obtained were
translated back into English for analysis. In the current manu-
script, we report the impact on patients and changes in their
behaviour and activity in response to hypoglycaemic
episodes.
2.5. Hypoglycaemia classification
Categories of hypoglycaemia recorded in the questionnaire
and patient diary included non-severe hypoglycaemia,
defined as an event based on either symptoms or self-
monitored blood glucose <56 mg/dL (3.1 mmol/L), and man-
aged by the patient alone; severe hypoglycaemia, defined,
based on the ADA definition, as any hypoglycaemic event
requiring assistance of another person to administer carbohy-
drate, glucagon or other resuscitative actions actively [21];
and nocturnal hypoglycaemia, any event occurring between
midnight and 06.00 h. A combined measure of any hypogly-
caemia, based on the sum of all individual hypoglycaemic
events of any category, was calculated based on questionnaire
entries. If a patient recorded more hypoglycaemic events
using the patient diary than the Part 2 SAQ, the patient diary
valuewas used to calculate the incidence of hypoglycaemia in
the 4 weeks after baseline to compensate for potential under-
estimates due to recall bias.
2.6. Statistical analysis
The proportion of patients who knew what hypoglycaemia
was before they read the definition provided in the Part 1
SAQ (see Description of hypoglycaemia in the introduction
to Part 1 SAQ in supplementary material) was summarised
by diabetes type. Hypoglycaemic fear was summarised overall
or bywhether or not patients had experienced severe hypogly-
caemia in the 6 months before baseline, and by diabetes type.
Pre-planned patient outcomes to assess the impact of
hypoglycaemic events included consultation with a health-care provider, requirement of medical assistance, increase
in calorie intake, avoidance of physical exercise, reduction
of insulin doses, skipping of insulin injections, and increased
blood glucose monitoring. Additional outcome measures
included sick leave and time lost from work or studies.
Summary statistics (n, mean, SD, lower quartile, median,
upper quartile, minimum, maximum, and the number miss-
ing) were calculated.
3. Results
3.1. Patient characteristics
A total of 27,585 patients (8022 type 1 diabetes; 19,563 type 2
diabetes) were enrolled, and completed Part 1 of the SAQ. Of
these, 25,505 patients (7070 [88.1%] type 1 diabetes; 18,435
[94.2%] type 2 diabetes) completed Part 2 and 23,627 patients
(6822 [85.0%] type 1 diabetes; 16,805 [85.9%] type 2 diabetes)
completed the patient diary. Baseline disposition is sum-
marised in Table 1. Patients’ baseline characteristics by region
for type 1 diabetes and type 2 diabetes are shown in Tables S1
and S2, respectively.3.2. Patient beliefs about the nature of hypoglycaemia
A total of 96.8% (n = 7711) of patients with type 1 diabetes and
85.6% (n = 16,577) of patients with type 2 diabetes were able to
define hypoglycaemia before reading the definition provided.
In terms of their prior personal definition of hypoglycaemia,
49.1% (n = 3758) of patients with type 1 diabetes and 42.3%
(n = 6231) of patients with type 2 diabetes incorporated both
symptoms and blood glucose measurements (Table 1).3.3. Rates of hypoglycaemia
Estimated annual rates of any hypoglycaemia in the prospec-
tive period were 73.3 events PPY (95% CI 72.6–74.0) and 19.3
events PPY (95% CI 19.1–19.6) for patients with type 1 diabetes
and type 2 diabetes, respectively (detailed results in Khunti
et al. [25]).
Regional overall hypoglycaemia rates for type 1 diabetes
were 91.6 events PPY (95% CI 90.0–93.2) for Northern Europe/
Canada, 66.9 events PPY (95% CI 65.8–67.9) for Eastern Europe,
93.9 events PPY (95% CI 90.6–97.3) for Latin America, 66.2
events PPY (95% CI 64.4–68.1) for the Middle East, 69.2 events
PPY (95% CI 66.8–71.6) for Russia, and 17.5 events PPY (95% CI
15.5–19.6) for SE Asia.
Regional overall hypoglycaemia rates for type 2 diabetes
were 18.1 events PPY (95% CI 17.6–18.7) for Northern Europe/
Canada, 23.7 events PPY (95% CI 23.2–24.1) for Eastern Europe,
19.7 events PPY (95% CI 18.9–20.6) for Latin America, 15.4
events PPY (95% CI 14.9–15.9) for the Middle East, 28.1 events
PPY (95% CI 26.8–29.6) for Russia, and 14.6 events PPY (95% CI
14.2–15.1) for SE Asia.3.4. Fear of hypoglycaemia
At baseline, mean ± SD scores for self-rated fear of hypogly-
caemia were 4.7 ± 3.0 for patients with type 1 diabetes and
Table 1 – Characteristics of the study population.
Characteristic Type 1 diabetes (n = 8022) Type 2 diabetes (n = 19,563)
Sex male/female, % 48/52 53/47
Mean age, years (SD) 42.1 (15.1) 60.8 (10.9)
Median (upper quartile, lower quartile) 40 (53, 30) 61 (68, 54)
Duration of diabetes, years (SD) 17.6 (12.0) 13.7 (8.2)
Median (upper quartile, lower quartile) 15 (24, 8) 12 (18, 8)
HbA1c, %
* (SD) 7.9 (1.5) 8.0 (1.5)
HbA1c, mmol/mol (SD) 62.8 (16.2) 64.2 (16.3)
Median (upper quartile, lower quartile) 61.0 (70.5, 51.9) 61.8 (72.7, 53.0)
Checks blood sugar levels, n (%)
Yes 7888 (98.6) 17,858 (91.6)
No 110 (1.4) 1635 (8.4)
Experienced hypoglycaemia, n (%)
Yes 7759 (97.4) 15,167 (78.3)
No 159 (2.0) 3272 (16.9)
Not sure 49 (0.6) 940 (4.9)
Defined hypoglycaemia on basis of, n (%)
Symptoms only 2051 (26.8) 5251 (35.6)
Blood glucose measurement only 300 (3.9) 1066 (7.2)
Either 1545 (20.2) 2195 (14.9)
Both 3758 (49.1) 6231 (42.3)
* Calculated, not measured. SD, standard deviation.
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6.7% of patients with type 1 diabetes and type 2 diabetes,
respectively, reported a level of fear of hypoglycaemia as
‘absolutely terrified’. The proportion of patients (type 1 and
2 diabetes combined) with no history of severe hypogly-
caemia reporting ‘not afraid at all’ was 15.8%, whilst 5.6%
were ‘absolutely terrified’. Among patients (type 1 and 2 dia-
betes combined) with a history of severe hypoglycaemia, the
proportion who reported their level of fear as ‘not afraid at
all’ was 6.2%, whilst 12.2% were ‘absolutely terrified’.
Regional differences in patients’ fear of hypoglycaemia
were evident (Table S3), with patients in Northern Europe
and Canada having the lowest mean scores both for patients
with type 1 diabetes and those with type 2 diabetes (3.9 and
2.9, respectively) and patients in the Middle East having the
highest mean scores (5.5 for type 1 diabetes and 5.4 for type
2 diabetes).Fig. 1 – Patient actions resulting from hypogly3.5. Patient actions
Patients’ actions in response to experiencing hypoglycaemia
varied between regions (Figs. 1 and 2). Regional trends with
regard to consulting their doctor/nurse, and/or requiring
medical assistance (Fig. 2A and B) for both, approximately
half to two-thirds of patients responded to hypoglycaemia
in these ways in all regions, except Northern Europe/Canada,
where these responses were substantially less common (one-
third of patients or fewer). In all regions, patients with type 2
diabetes were more likely to consult their doctor/nurse or
require medical assistance than patients with type 1 diabetes
(Fig. 2A and B).
The proportion of patients who avoided physical exercise
in response to hypoglycaemia also varied between regions,
with approximately one-third doing so in Russia and SE Asia
compared with <10% in Northern Europe/Canada (Fig. 2D).caemia in the 4 weeks following baseline.
Fig. 2 – Regional breakdowns for patients who A: consulted their doctor/nurse, B: required any form of medical assistance, C:
increased calorie intake, D: avoided physical exercise, E: reduced insulin dose, F: missed an injection, and G: increased blood
glucose monitoring in response to hypoglycaemia during the prospective period.
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glycaemia in all regions, ranging from 33.6% to 51.7% in
patients with type 1 diabetes and from 25.8% to 46.7% in
patients with type 2 diabetes (Fig. 2E). In all regions, a greater
proportion of patients with type 1 diabetes reduced their
insulin dose in response to a hypoglycaemic event compared
with patients with type 2 diabetes. However, the extent of this
difference varied between regions, with patients with type 2diabetes in the Middle East almost as likely to reduce insulin
dose as those with type 1 diabetes (46.7% vs. 47.6%, respec-
tively), whereas in Northern Europe/Canada, patients with
type 2 diabetes were considerably less likely to reduce insulin
dose than patients with type 1 diabetes (25.8% vs. 43.0%,
respectively).
There was considerable variation between the regions in
the proportion of patients who missed an injection in
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diabetes; 6.9–21.8% for patients with type 2 diabetes) (Fig. 2F).
This response was most common in SE Asia. In five out of six
regions, patients with type 1 diabetesweremore likely to miss
an injection than those with type 2 diabetes; Latin America
was the exception.
Finally, high proportions of patients across all regions
increased blood glucose monitoring following hypoglycaemia
(Fig. 2G), and this response was more common in patients
with type 1 diabetes (69.7% globally) than with type 2 diabetes
(60.9% globally). The duration of additional monitoring lasted
for 2.7 ± 4.3 days and 1.8 ± 3.2 days for type 1 and type 2 dia-
betes, respectively.
3.6. Impact of hypoglycaemia on the medical system, and
on work and study
Globally, 2.1% of patients with type 1 diabetes and 3.4% of
patients with type 2 diabetes had a hypoglycaemic event
requiring hospital admission in the 4 weeks following base-
line, whereas 3.8% and 6.8%, respectively, attended additional
clinic appointments as a result of hypoglycaemia. Additional
telephone contacts to medical personnel as a result of hypo-
glycaemia were reported by 8.8% of patients with type 1 dia-
betes and 16.0% of patients with type 2 diabetes. Of those
patients who took leave from work or study as a result of
hypoglycaemia, patients with type 1 diabetes reported taking
a mean 2.0 days off work or study in the 1-month prospective
period, and patients with type 2 diabetes reported taking a
mean 1.8 days off work or study due to hypoglycaemia in
the 1-month prospective period (Tables S4 and S5).
4. Discussion
The HAT real-world study, the largest prospective observa-
tional study of hypoglycaemia to date, has demonstrated glo-
bal hypoglycaemia rates higher than previously reported from
studies focused on Western countries [18,20,26], with the
highest rates in patients with type 1 diabetes in Northern Eur-
ope and Canada, and Latin America, and the highest rates in
patients with type 2 diabetes in Russia and Eastern Europe
(these data are discussed in more detail in Khunti et al.
[25]). In addition, the results show that hypoglycaemia influ-
enced patient behaviour that could affect both glycaemic con-
trol and the cost burden to healthcare systems, with
approximately half of all patients saying they consulted a
doctor or nurse and almost half of patients with type 1 dia-
betes reduced insulin dose as a result of hypoglycaemia. A
sizeable proportion (>40%) of patients who experienced a
hypoglycaemic event in the prospective period said that they
consulted a doctor/nurse, required medical assistance,
increased calorie intake or increased blood glucose monitor-
ing. There were notable differences in patient responses
across geographic regions. Patients with a history of severe
hypoglycaemia within the previous 6 months were more
likely to report greater fear of hypoglycaemia than thosewith-
out a history of severe hypoglycaemia. Overall, 7.4% and 6.7%
of patients with type 1 diabetes and type 2 diabetes, respec-
tively, reported their level of fear of hypoglycaemia as ‘abso-
lutely terrified’. This finding is of note given that the studycomprised a large multinational population of more than
25,000 patients. Overall, an increase in fear of hypoglycaemia
was seen for patients with a history of severe hypoglycaemia
compared with those without. Fear of hypoglycaemia also
varied between regions, being generally higher in regions out-
side of Europe and Canada, but these were not necessarily the
regions with the highest rates of hypoglycaemia [25]).
Limitations of this study include its observational nature
and short prospective duration. More importantly, such a trial
design allowed for a large, multinational patient population to
complete the study and offered the possibility to examine
country-specific differences in a global population. The use
of diary-based data in the prospective period may have
increased the reliability of data on incidence and prevalence
of hypoglycaemia and patient actions, although taking the
highest of the patient-reported values for hypoglycaemia inci-
dence could potentially overestimate hypoglycaemia rates in
this study. Furthermore, the use of self-reported patient ques-
tionnaires and diaries could introduce bias into the popula-
tion, depending on willingness to participate and local
literacy rates.
Similar to previous self-reporting studies, patients in the
HAT study were permitted to record hypoglycaemia by either
symptoms or blood glucose testing alone, or in combination.
This is both a strength and a limitation of the study. Including
episodes of hypoglycaemia on the basis of symptoms alone
captures events in which patients forgot or neglected to test
blood glucose, were unaware of the blood glucose concentra-
tion cut-off for hypoglycaemia, or were unable to test due to a
lack of testing devices/materials. However; the subjective nat-
ure of patients self-defining hypoglycaemia on the basis of
symptoms alone introduces the potential for confounding
due to differences in the levels of patient education regarding
hypoglycaemia cut-offs. Similarly, differences in healthcare
provision and local economic conditions could affect access
to patient education and blood glucose monitoring materials,
which in turn could affect recording of hypoglycaemic epi-
sodes. A high-level of education regarding hypoglycaemia
could be defined as an understanding that hypoglycaemia
can occur independently for both blood glucose cut-offs and
symptoms, and this may not be the case for a large proportion
of the study population. However, these factors, patient edu-
cation and healthcare provision, are also highly likely to affect
the incidence of hypoglycaemia.
The changes in patient behaviour in response to hypogly-
caemia reported here have been previously observed in
response to both nocturnal [6] and overall non-severe hypo-
glycaemia [7,13,27]. Greater fear of hypoglycaemia reported
by patients with a history of severe hypoglycaemia is consis-
tent with previous reports [28]. However, this global study has
identified considerable regional differences in patients’
responses to hypoglycaemia, suggesting that the manage-
ment and importance of hypoglycaemia differs markedly in
different parts of the world, and underlining the importance
of gathering regional data in order to individualise interven-
tions and educational measures.
The patient actions in response to hypoglycaemia reported
here (consulting a doctor/nurse, requiring medical assistance,
increasing calorie intake or increasing blood glucose monitor-
ing) could result in increased costs for the patient and/or the
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 3 0 ( 2 0 1 7 ) 1 2 1 –1 2 9 127healthcare system, or hinder achievement of good glycaemic
control.
Patients in SE Asia were least likely to increase blood glu-
cose monitoring in response to hypoglycaemia, which could
reflect the local healthcare systems and cost burden of blood
glucose testing for patients. In Northern Europe and Canada,
where patients had the lowest fear of hypoglycaemia, despite
higher actual rates of hypoglycaemia, substantially fewer
patients consulted a doctor or nurse, or required medical
assistance as a result of hypoglycaemia, which may reflect a
high level of patient education and ability to self-manage
their diabetes. In other countries, an underlying reason may
be a reluctance to go to the doctor due to the costs for the
patient associated with the clinic visit. Interestingly, the
regions that had the greatest numbers of patients missing
insulin injections, avoiding physical exercise or increasing
calorie intake in response to hypoglycaemia (activities that
may adversely impact treatment) and those regions with the
greatest number of patients consulting a doctor or nurse,
were also those with the greatest fear of hypoglycaemia. Fear
of hypoglycaemia led patients to take actions that may have
hampered glycaemic control, suggesting that a substantial
proportion of patients with diabetes worldwide could be pre-
vented from achieving individual treatment goals [9,29]. How-
ever, caution should be used in interpreting these results, as
they could be due to a variety of factors such as culture,
genetics, diet, lifestyle, available treatments, healthcare and
reimbursement systems, and access to relevant information
and support. Patient education is important to prevent hypo-
glycaemia adequately and to ensure that actions in response
to hypoglycaemia do not adversely impact treatment, but
instead result in improved self-management and appropriate
use of available support. Self-management programmes have
been shown to reduce hypoglycaemia in trials of intensive
treatment, while also achieving tighter glycaemic control
[30–32].
Although this study identified considerable regional differ-
ences in patient response to hypoglycaemia that may affect
the cost and effectiveness of treatment, the underlying rea-
sons remain to be determined. Further studies and analyses
are required to investigate the contributions of cultural differ-
ences and differences in healthcare approaches. Understand-
ing the true frequency of hypoglycaemia and its impact on
patient behaviour in different parts of the world will be an
important part of tailoring insulin treatment for patients with
diabetes.
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